Spots Global Cancer Trial Database for cmml
Every month we try and update this database with for cmml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT01261312 | MDS CMML AML | SGI-110 SGI-110 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | NCT00074750 | Acute Myelogeno... Chronic Myelomo... | DTGM | 18 Years - | M.D. Anderson Cancer Center | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) | NCT03040401 | Leukemia, Myelo... | Cohort 1, Ceple... Cohort 2, Ceple... Cohort 3, Ceple... | 18 Years - | Vastra Gotaland Region | |
| Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | NCT00920140 | Cancer | GSK1120212 GSK1120212 | 18 Years - | GlaxoSmithKline | |
| 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | NCT01404741 | Myelodysplastic... Chronic Myelomo... | allogeneic stem... 5-azacytidine u... | 55 Years - 70 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | NCT03493646 | Myelodysplastic... Acute Myeloid L... Chronic Myelomo... | Azacitidine CC-486 | 18 Years - | Kirby Institute | |
| Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | NCT00299156 | Myelodysplastic... Chronic Myelomo... | Clofarabine | - | M.D. Anderson Cancer Center | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | NCT00074750 | Acute Myelogeno... Chronic Myelomo... | DTGM | 18 Years - | M.D. Anderson Cancer Center | |
| Registry on Hypomethylating Agents in Myeloid Neoplasms | NCT01595295 | Chronic Myelomo... Myelodysplastic... Acute Myeloid L... | non interventio... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | NCT01404741 | Myelodysplastic... Chronic Myelomo... | allogeneic stem... 5-azacytidine u... | 55 Years - 70 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | NCT03493646 | Myelodysplastic... Acute Myeloid L... Chronic Myelomo... | Azacitidine CC-486 | 18 Years - | Kirby Institute | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | NCT04358393 | AML Acute Myeloid L... Chronic Myelomo... CMML Myelodysplastic... High-risk Myelo... MDS | APG-115 5-azacitidine | 18 Years - | Ascentage Pharma Group Inc. | |
| A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) | NCT03040401 | Leukemia, Myelo... | Cohort 1, Ceple... Cohort 2, Ceple... Cohort 3, Ceple... | 18 Years - | Vastra Gotaland Region | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | NCT02193958 | AML CMML MDS | FF-10501-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | NCT02010645 | Leukemia | Eltrombopag Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | NCT00043381 | Myelodysplastic... | decitabine (5-a... | 18 Years - | Astex Pharmaceuticals, Inc. | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients | NCT02367456 | Myelodysplastic... Acute Myeloid L... Chronic Myelomo... | PF-04449913 (Gl... Azacitidine | 18 Years - | Pfizer | |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | NCT00664677 | Leukemias Acute Myeloid L... Acute Lymphocyt... Adult T Cell Le... Chronic Myeloid... Chronic Lymphoc... Myelodysplastic... Chronic Myelomo... | Terameprocol (E... | 18 Years - | Erimos Pharmaceuticals | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) | NCT05768711 | Chronic Myeloid... | Venetoclax | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia | NCT00079313 | Chronic Myelomo... Chronic Myeloge... | Imatinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | NCT00946647 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | Panobinostat (L... 5-Azacytidine | 18 Years - | Novartis | |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | NCT02841540 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | H3B-8800 (RVT-2... | 18 Years - | Hemavant Sciences GmbH | |
| Tagraxofusp (SL-401) in Patients With CMML or MF | NCT02268253 | Myelofibrosis Chronic Myelomo... | SL-401 | 18 Years - | Stemline Therapeutics, Inc. | |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | NCT01613976 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | Panobinostat | 20 Years - | Novartis | |
| Lenalidomide in Patients With Chronic Myelomonocytic Leukemia | NCT01368757 | Chronic Myelomo... | Revlimid | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | NCT02841540 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | H3B-8800 (RVT-2... | 18 Years - | Hemavant Sciences GmbH | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | NCT00920140 | Cancer | GSK1120212 GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS | NCT02969980 | Myelodysplastic... | Cyclophosphamid... | 15 Years - | Asan Medical Center | |
| Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) | NCT05768711 | Chronic Myeloid... | Venetoclax | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS | NCT02969980 | Myelodysplastic... | Cyclophosphamid... | 15 Years - | Asan Medical Center | |
| Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | NCT03722407 | Chronic Myelomo... Leukemia | Ruxolitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | NCT01519011 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | oral azacitidin... oral azacitidin... | 18 Years - | Celgene | |
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | NCT04891757 | Advanced Hemato... Relapsed Acute ... Refractory Acut... Relapsed Myelod... Refractory Myel... Relapsed Chroni... Refractory Chro... | FHD-286 Low Dose Cytara... Decitabine | 16 Years - | Foghorn Therapeutics Inc. | |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | NCT04358393 | AML Acute Myeloid L... Chronic Myelomo... CMML Myelodysplastic... High-risk Myelo... MDS | APG-115 5-azacitidine | 18 Years - | Ascentage Pharma Group Inc. | |
| Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL | NCT02147873 | Myelodysplastic... Chronic Myelomo... | birinapant Azacitidine Placebo | 18 Years - | TetraLogic Pharmaceuticals | |
| A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | NCT02418000 | AML MDS CMML | E6201 | 18 Years - | Spirita Oncology, LLC | |
| Ascorbic Acid Levels in MDS, AML, and CMML Patients | NCT03526666 | Myelodysplastic... Acute Myeloid L... Chronic Myelomo... MDS AML CMML | Peripheral bloo... | 18 Years - | Van Andel Research Institute | |
| Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy | NCT06439199 | Acute Myeloid L... Myelodysplastic... Chronic Myelomo... | 18 Years - 99 Years | Nantes University Hospital | ||
| Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | NCT02193958 | AML CMML MDS | FF-10501-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | NCT03493646 | Myelodysplastic... Acute Myeloid L... Chronic Myelomo... | Azacitidine CC-486 | 18 Years - | Kirby Institute | |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | NCT04996875 | Advanced System... SM With an Asso... Mast Cell Leuke... Aggressive Syst... | bezuclastinib | 18 Years - | Cogent Biosciences, Inc. | |
| Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | NCT05807932 | Myelodysplastic... Secondary Acute... Chronic Myelomo... | Venetoclax Amsacrine Ara-C Tacrolimus Mycophenolate M... | 18 Years - | Heinrich-Heine University, Duesseldorf | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Registry on Hypomethylating Agents in Myeloid Neoplasms | NCT01595295 | Chronic Myelomo... Myelodysplastic... Acute Myeloid L... | non interventio... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia | NCT01350947 | Chronic Myelomo... | 5-Azacitidine | 18 Years - | University of Utah | |
| Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML | NCT06267898 | MDS CMML | 18 Years - | European Society for Blood and Marrow Transplantation | ||
| Lenalidomide in Patients With Chronic Myelomonocytic Leukemia | NCT01368757 | Chronic Myelomo... | Revlimid | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT | NCT02472691 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | Lenalidomide Azacitidine Donor Lymphocyt... | 18 Years - 99 Years | Heinrich-Heine University, Duesseldorf | |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | NCT02841540 | Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo... | H3B-8800 (RVT-2... | 18 Years - | Hemavant Sciences GmbH | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | NCT00136409 | Myelofibrosis Myeloid Metapla... Agnogenic Myelo... Chronic Myelomo... | Imatinib mesyla... | 18 Years - | Dana-Farber Cancer Institute | |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers | NCT04093570 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... | ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
